公开(公告)号：US20240309012A1

公开(公告)日：2024-09-19

申请号：US18009981

申请日：2021-01-11

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences ,  Wuhan Institute of Virology, Chinese Academy of Science

发明人： Jingshan SHEN ,  Zhaobing GAO ,  Gengfu XIAO ,  Jia LI ,  Feipu YANG ,  Leike ZHANG ,  Bingqing XIA ,  Xiangrui JIANG ,  Yang HE ,  Hualiang JIANG

IPC分类号： C07D491/18 ,  A61K31/4748 ,  A61P31/14 ,  C07D491/22 ,  C07D498/22 ,  C07D519/00

CPC分类号： C07D491/18 ,  A61K31/4748 ,  A61P31/14 ,  C07D491/22 ,  C07D498/22 ,  C07D519/00

摘要： Provided are an isoquinoline compound represented by formula (I), a pharmaceutically acceptable salt thereof, an enantiomer thereof, a diastereomer, a racemate, a crystalline hydrate, and a solvate, as well as an application of a composition thereof in fighting a virus. R1, R2, R3, and R4 are as defined in the description. Further provided are a preparation method for the compound and uses thereof for preparing an inhibitor that inhibits a virus and/or a drug for prophylaxis and/or treatment of an illness related to a respiratory tract infection, pneumonia, etc. caused by a virus.

公开(公告)号：US20230219993A1

公开(公告)日：2023-07-13

申请号：US17996430

申请日：2021-04-16

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCE ,  XINJIANG TECHNICAL INSTITUTE OF PHYSICS AND CHEMISTRY, CHINESE ACADEMIY OF SCIENCES ,  VIGONVITA LIFE SCIENCES CO., LTD.

发明人： Yuanchao XIE ,  Gengfu XIAO ,  Yang HE ,  Leike ZHANG ,  Heji Akber AISA ,  Hualiang JIANG ,  Jingshan SHEN

IPC分类号： C07H7/06 ,  A61P31/14 ,  A61P31/16

CPC分类号： C07H7/06 ,  A61P31/14 ,  A61P31/16 ,  C07B2200/05

摘要： The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia
(COVID-19) and other related diseases caused by 2019 novel coronavirus infection.

公开(公告)号：US11919923B2

公开(公告)日：2024-03-05

申请号：US17996430

申请日：2021-04-16

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCE ,  XINJIANG TECHNICAL INSTITUTE OF PHYSICS AND CHEMISTRY, CHINESE ACADEMY OF SCIENCES ,  VIGONVITA LIFE SCIENCES CO., LTD.

发明人： Yuanchao Xie ,  Gengfu Xiao ,  Yang He ,  Leike Zhang ,  Haji Akber Aisa ,  Hualiang Jiang ,  Jingshan Shen

IPC分类号： C07H7/06 ,  A61P31/14 ,  A61P31/16

CPC分类号： C07H7/06 ,  A61P31/14 ,  A61P31/16 ,  C07B2200/05

摘要： The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia (COVID-19) and other related diseases caused by 2019 novel coronavirus infection.